Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jim Canet"'
Autor:
Jim Canet, Pascale Cony‐Makhoul, Sébastien Orazio, Edouard Cornet, Xavier Troussard, Marc Maynadié, Gabriel Étienne, Alain Monnereau
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 6959-6970 (2021)
Abstract Introduction Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new‐generation TKI (NG‐TKI) compared to those treated with imatinib (IM). Are the same results observed in the genera
Externí odkaz:
https://doaj.org/article/7a42a142a28b4530b3548b33ce3196de
Autor:
Raphaëlle Teysseire, Guyguy Manangama, Jim Canet, Fleur Delva, Loïc Sentilhes, Marion Lecourt
Publikováno v:
International Journal of Environmental Research and Public Health, Vol 16, Iss 4, p 565 (2019)
International Journal of Environmental Research and Public Health
Volume 16
Issue 4
International Journal of Environmental Research and Public Health
Volume 16
Issue 4
Limiting exposure to environmental hazards during preconception and pregnancy is essential for preventing adverse pregnancy outcomes or developmental defects in offspring. However, the perception of environmental risk and the behavioral changes of wo
Autor:
Janick Selves, Wulfran Cacheux, Aurélie Cartier, Ivan Bièche, Leanne de Koning, Frédérique Berger, Bérengère Ouine, Yael Amar, Odette Mariani, Rosine Guimbaud, Jim Canet, Thierry Lecomte, Astrid Lièvre, Serge Guyetant
Publikováno v:
British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2017, 117 (12), pp.1819-1827. ⟨10.1038/bjc.2017.353⟩
British Journal of Cancer, 2017, 117 (12), pp.1819-1827. ⟨10.1038/bjc.2017.353⟩
British Journal of Cancer, Cancer Research UK, 2017, 117 (12), pp.1819-1827. ⟨10.1038/bjc.2017.353⟩
British Journal of Cancer, 2017, 117 (12), pp.1819-1827. ⟨10.1038/bjc.2017.353⟩
International audience; Background: Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57c7b2f0ea07fe67f5afd47f375f8dc8
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01682154/file/Lievre_merged_20102017.pdf
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01682154/file/Lievre_merged_20102017.pdf
Autor:
Astrid Lièvre, Bérèngere Ouine, Jim Canet, Aurélie Cartier, Yael Amar, Wulfran Cacheux, Odette Mariani, Rosine Guimbaud, Janick Selves, Thierry Lecomte, Serge Guyetant, Ivan Bieche, Frédérique Berger, Leanne de Koning
Publikováno v:
British Journal of Cancer
Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGFR and induce primary resistance. How